ConductScience.org, home

Paper8575795

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Kashmiri SV and 5 others. Hybridoma, 1995. Cited by 70 papers, by iCite.

Cite this record

ConductScience Library. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Papers, record 8575795. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8575795

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
PubMed
Journal
Hybridoma
PubMed
Year
1995
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
70
iCite
Relative citation ratio, by iCite
2.04
iCite
Revised in PubMed
2006-04-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kashmiri SVS V
2Shu LL
3Padlan EAE A
4Milenic DED E
5Schlom JJ
6Hand PHP H

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antibodies, NeoplasmMajor topic
Amino Acid Sequence
Animals
Antigens, Neoplasm
Base Sequence
Binding, Competitive
Female
Genes, Immunoglobulin
Genetic Vectors
Glycoproteins
Humans
Immunoglobulin Heavy Chains
Immunoglobulin Light Chains
Immunoglobulin Variable Region
Mice
Mice, Nude
Molecular Sequence Data
Radioimmunoassay
Recombinant Fusion Proteins
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.

PMIDTitleJournalYearIn PapersSource
40925376Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors.Cell Rep Med2025https://conductscience.org/library/papers/40925376PubMed
37509200Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.Cancers (Basel)2023https://conductscience.org/library/papers/37509200PubMed
35158915Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.Cancers (Basel)2022https://conductscience.org/library/papers/35158915PubMed
33614914Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer.Mol Ther Oncolytics2021https://conductscience.org/library/papers/33614914PubMed
32217350Humanized Anti-Tumor-Associated Glycoprotein-72 for Submillimeter Near-Infrared Detection of Colon Cancer in Metastatic Mouse Models.J Surg Res2020https://conductscience.org/library/papers/32217350PubMed
30510550Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.Front Immunol2018https://conductscience.org/library/papers/30510550PubMed
30052649Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.PLoS One2018https://conductscience.org/library/papers/30052649PubMed
28344808Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.J Immunother Cancer2017https://conductscience.org/library/papers/28344808PubMed
23015323Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.Mol Biotechnol2013https://conductscience.org/library/papers/23015323PubMed
20980835Identification of a high affinity TAG-72 binding peptide by phage display selection.Cancer Biol Ther2011https://conductscience.org/library/papers/20980835PubMed
19173715A comprehensive overview of radioguided surgery using gamma detection probe technology.World J Surg Oncol2009https://conductscience.org/library/papers/19173715PubMed
19019238Gamma probes and their use in tumor detection in colorectal cancer.Int Semin Surg Oncol2008https://conductscience.org/library/papers/19019238PubMed
18309354Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes.Cancer Gene Ther2008https://conductscience.org/library/papers/18309354PubMed
17034135Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.J Med Chem2006https://conductscience.org/library/papers/17034135PubMed
15846298HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.Br J Cancer2005https://conductscience.org/library/papers/15846298PubMed
10596374Generation of recombinant antibodies.Mol Biotechnol1999https://conductscience.org/library/papers/10596374PubMed

Download CSV of cited by

Data2

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccessionSource
GENBANKS81415GENBANK
GENBANKS81417GENBANK

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8575795

GET https://conductscience.org/api/papers/v1/8575795/authors